Abstract library

21 results for "committee".
#2277 Neuroendocrine Tumors Committee of Reference Hospital: Decision-Making Process on the Diagnostic and Therapeutic Approach to Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) require a multidisciplinary approach in expert centers due to their rarity, heterogeneity and the lack of evidence about optimal clinical management.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PhD Paula Jimenez-Fonseca
Authors:
#1943 Neuroendocrine Tumors Committee of Reference Hospital: Evaluation of Health Care and Research Indicators
Introduction: Neuroendocrine tumors (NETs) require a multidisciplinary approach in expert centers which optimize results improving care and survival.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD-PhD Paula Jimenez Fonseca
Authors:
#1326 Clinical Nurse Specialist in NET Patients at Institut Català d’ Oncologia - ICO
Introduction: A Functional Unit model brings together multidisciplinary professionals participating in a committee. Its aim is to optimize diagnostic and therapeutic intervals, get consensus on the best-individual treatment option & best evidence. Our unit-NET, was establish 10 years ago & last 4 got a clinical nurse specialist-CNS
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: RN, PhDcandidate Paz Fernandez
Authors:
Keywords: Clinical nurse
#2070 The Impact of NETwerk on the Multidisciplinary Tumor Boards
Introduction: Since 2016, nine hospitals from the Belgian region Antwerp-Waasland collaborate with the aim to optimize treatment of neuroendocrine tumor patients. NET cases are biweekly discussed by NET experts at a NET specific multidisciplinary tumor board (NET MDT). This collaboration (NETwerk) obtained a certificate of ENETS Center of Excellence in 2017.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Marc Peeters
Authors:
#2079 Excellent Survival Outcomes for NET Patients Treated within NETwerk, a Collaborative ENETS Center of Excellence
Introduction: Since 2016, patients with neuroendocrine tumors (NETs) of 9 hospitals in Belgium, are jointly discussed during multidisciplinary tumor boards (NET MDT) within NETwerk, a ENETS Center of Excellence.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Marc Peeters
Authors:
#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
Authors:
#217 Risk of Metastatic Spread in Patients with Early-Stage, Surgically Resected Pancreatic Neuroendocrine Tumors
Introduction: The risk of metastatic spread among patients with early-stage surgically resected pancreatic neuroendocrine tumors has not been well-established.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
Authors:
#399 Malignant Carotid Body Tumors (CBTs), Clinical Presentation, Investigations and Their Management
Introduction: Malignant CBTs are rare (incidence 0.012%) and their management is not well settled. We present 2 pts. with malignant CBTs to define their presentation, investigations done and treatment undertaken w/ FU.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Mohammed Ahmed
Authors:
#554 Analysis of the AJCC/ENETS Staging Classification for Midgut Neuroendocrine Tumors
Introduction: The American Joint Committee on Cancer (AJCC) and ENETS have independently introduced a novel TNM staging classification for jejunal-ileal NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Max Feldman
Authors:
#627 Pancreatic Neuroendocrine Tumors: Two Different TNM Staging Systems
Introduction: Several staging systems for pancreatic neuroendocrine tumors (PNETs) exist but the most appropriate one has not been defined.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: Elena Martin-Perez
Authors: